The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated•Originally published 13 April 2026•Updated 15 April 2026•

1 min read

FDA Grants Full Approval for Travere Therapeutics' Filspari for FSGS Treatment

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1The U.S. FDA granted expanded approval for Travere Therapeutics' drug to treat a rare kidney disorder.

Travere Therapeutics has secured full FDA approval for its drug Filspari to treat Focal Segmental Glomerulosclerosis (FSGS), a rare kidney condition. Following the announcement, the company's stock price surged by 37%, reflecting strong investor confidence in the drug's commercial potential. This regulatory milestone expands Travere's U.S. addressable market by approximately 30,000 patients, significantly boosting its revenue outlook. Filspari features a unique non-immunosuppressive mechanism of action, granting the company first-mover status in the FSGS treatment landscape. Industry analysts view the full approval as a major catalyst for long-term growth and clinical adoption. The market response underscores the strategic importance of this development for TVTX's specialized pharmaceutical portfolio.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: Updated the story to specify Filspari's full approval for FSGS, the 37% stock surge, the addition of 30,000 potential patients, and its unique mechanism of action.